SCHEMBL6380266

SCHEMBL6380266

COC(=O)CCc1ccc(OCCn2ccc3ccccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.54
FFAR1 O14842 1/20 0.54
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SMPD1 P17405 1/20 0.49
MAPK1 P28482 3/20 0.48
PTPN1 P18031 2/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6380447 0.88 FFAR1 (0.56) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL6485358 0.84 MTNR1A (0.51) PPARGMEN1KMT2ALMNAMAPT
SCHEMBL6379239 0.81 SMN1; SMN2 (0.60) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL6383661 0.81 PPARG (0.63) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL6380437 0.80 PPARG (0.53) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL2037341 0.80 LMNA (0.65) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL6379227 0.79 FFAR1 (0.56) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL6380456 0.78 PPARG (0.57) PPARGFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL22610155 0.78 CDK4 (0.60) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL13932451 0.77 FFAR1 (0.60) PPARGFFAR1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US claimed
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity LIPC, CPT1A, GPR119 PPARG 127/4885FFAR1 63/4885NPC1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.